Aug 27, 2026 09:44AM
Aug 27, 2026 08:00AM
Aug 18, 2026 08:00AM
Aug 18, 2026 08:00AM
Aug 7, 2026 04:05PM
Aug 4, 2026 08:30AM
Aug 4, 2026 08:30AM Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at th
Jul 31, 2026 04:30PM
Jul 27, 2026 08:30AM
Jul 27, 2026 08:30AM
Jul 27, 2026 08:30AM
Jul 27, 2026 08:30AM
Jun 24, 2026 06:46AM
Jun 22, 2026 08:30AM FDA backs Entera Bio's Phase 3 trial plan for oral osteoporosis drug
Jun 22, 2026 08:30AM
Jun 16, 2026 08:33AM
Jun 16, 2026 08:33AM
Jun 15, 2026 08:45AM
Jun 15, 2026 08:45AM
Jun 15, 2026 08:45AM
May 28, 2026 08:50AM Entera Bio's EB613 data selected for presentation at ENDO 2026
May 28, 2026 08:50AM
May 8, 2026 04:05PM
Apr 14, 2026 08:45AM
Apr 2, 2026 08:46AM
Apr 2, 2026 08:45AM
Mar 27, 2026 04:05PM
Mar 4, 2026 08:30AM Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug
Mar 4, 2026 08:30AM
Feb 11, 2026 09:03AM
Feb 11, 2026 09:00AM
Feb 9, 2026 08:50AM
Feb 9, 2026 08:50AM
Feb 4, 2026 08:02AM
Feb 4, 2026 08:00AM OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
Jan 21, 2026 08:31AM
Jan 21, 2026 08:30AM
Jan 21, 2026 08:30AM
Dec 24, 2025 06:44AM
Dec 23, 2025 08:30AM
Dec 22, 2025 08:32AM
Dec 22, 2025 08:30AM Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Nov 18, 2025 08:00AM
Nov 14, 2025 04:05PM
Oct 23, 2025 08:50AM
Oct 23, 2025 08:50AM
Oct 16, 2025 08:45AM
Oct 16, 2025 08:45AM
Sep 15, 2025 09:01AM Entera Bio presents oral GLP-2 tablet data at medical conference
Sep 15, 2025 09:00AM

330,123 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All